RBM-007 is considered a potential new treatment for wet AMD patients with no prior treatment history!
We would like to introduce the clinical trials conducted by our company. As a clinical trial targeting exudative age-related macular degeneration (wet AMD), a Phase 2 clinical trial was conducted in the United States after the implementation of a Phase 1/2a clinical trial, aimed at confirming the clinical proof of concept (POC) of multiple administrations of RBM-007. Furthermore, a physician-led clinical trial was conducted in the United States to evaluate the efficacy and safety of RBM-007 monotherapy in treatment-naive wet AMD patients. 【Main Trials】 ■ Randomized double-blind trial ■ Open-label trial ■ Physician-led clinical trial *For more details, please refer to the PDF materials or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Our company is engaged in drug discovery business utilizing the drug discovery technology "RiboART System" to develop various new drugs that are not limited to specific diseases or target proteins. This drug discovery business consists of two components: in-house drug discovery and collaborative research with other pharmaceutical companies. For some drug candidates, we will conduct clinical trials in-house and, after obtaining Proof of Concept (POC), we will license them out to pharmaceutical companies.